Nanosyn Inc. and Amphora Discovery Corporation have announced that they have entered into a multi-year research collaboration whereby Nanosyn will provide chemistry-based services to Amphora Discovery for multiple drug targets.
Under the terms of the agreement Amphora will access a wide range of chemistry expertise offered by Nanosyn as well as their proprietary technologies allowing for design and synthesis of biologically relevant small molecules.
Amphora will own all compounds and their methods of use identified under the agreement.
Nanosyn will receive an upfront fee, research funding, and success milestone payments for novel series identified in the collaboration.
Nanosyn has already received success milestones from Amphora for two chemical scaffolds.
"We are keen to expand on the very successful partnership that we currently have in place with Nanosyn for rapid, cost-effective chemistry services," stated C. Nicholas Hodge, Ph.D., Chief Scientific Officer and Founder of Amphora Discovery.
"By extending the collaboration, we are able to tap into Nanosyn's full range of capabilities in complex, innovative chemistry. This relationship strengthens Amphora's ability to move multiple safe, targeted drugs into clinical trials."
"We are delighted to see that our relationship with Amphora Discovery has developed into a fully integrated chemistry collaboration," said Nikolai Sepetov, President and CEO of Nanosyn.
"I believe that Amphora's unique set of chemical biology tools and Nanosyn's chemistry capabilities are truly complementary, allowing for rapid advancement of drug discovery programs at Amphora."